By Kyle Morris

 

AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer.

The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan--has been recommended in the EU by the European Medicines Agency as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

 

Write to Kyle Morris at kyle.morris@dowjones.com

 

(END) Dow Jones Newswires

November 14, 2022 02:37 ET (07:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 12 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 1 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック